TriangleUbamatamab (NCT07154290)
Ubamatamab trial for Non Small Cell Lung Cancer (NCT07154290). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with previously treated advanced or metastatic non-small-cell lung cancer. Tumor tissue must be available for MUC16 testing. Platinum chemotherapy is required unless documented as unsuitable.
The idea: ubamatamab links T cells to MUC16-bearing tumor cells. Some randomized groups also receive marlotamig, which connects EGFR-bearing cells with a T-cell activation signal. Sarilumab is studied to manage immune-related side effects. Doses and schedules are not disclosed in the public record.
This phase 2 study plans 300 patients. Regeneron sponsors it, with 18 recruiting US sites. Researchers measure tumor response.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.